Literature DB >> 20829340

Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective American College of Surgeons Oncology Group Z0030 trial.

Gail E Darling1, Mark S Allen2, Paul A Decker2, Karla Ballman2, Richard A Malthaner3, Richard I Inculet3, David R Jones4, Robert J McKenna5, Rodney J Landreneau6, Joe B Putnam7.   

Abstract

BACKGROUND: Lymph node status is a major determinant of stage and survival in patients with lung cancer; however, little information is available about the expected yield of a mediastinal lymphadenectomy.
METHODS: The American College of Surgeons Oncology Group Z0030 prospective, randomized trial of mediastinal lymph node sampling vs complete mediastinal lymphadenectomy during pulmonary resection enrolled 1,111 patients from July 1999 to February 2004. Data from 524 patients who underwent complete mediastinal lymph node dissection were analyzed to determine the number of lymph nodes obtained.
RESULTS: The median number of additional lymph nodes harvested from a mediastinal lymphadenectomy following systematic sampling was 18 with a range of one to 72 for right-sided tumors, and 18 with a range of four to 69 for left-sided tumors. The median number of N2 nodes harvested was 11 on the right and 12 on the left. A median of at least six nodes was harvested from at least three stations in 99% of patients, and 90% of patients had at least 10 nodes harvested from three stations. Overall, 21 patients (4%) were found to have occult N2 disease.
CONCLUSIONS: Although high variability exists in the actual number of lymph nodes obtained from various nodal stations, complete mediastinal lymphadenectomy removes one or more lymph nodes from all mediastinal stations. Adequate mediastinal lymphadenectomy should include stations 2R, 4R, 7, 8, and 9 for right-sided cancers and stations 4L, 5, 6, 7, 8, and 9 for left-sided cancers. Six or more nodes were resected in 99% of patients in this study. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00003831; URL: clinicaltrials.gov.

Entities:  

Mesh:

Year:  2010        PMID: 20829340      PMCID: PMC3087457          DOI: 10.1378/chest.10-0859

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  16 in total

1.  Sampling or node dissection for intraoperative staging of lung cancer: a multicentric cross-sectional study.

Authors:  Gilbert Massard; Xavier Ducrocq; Evgenia A Kochetkova; Vladimir A Porhanov; Marc Riquet
Journal:  Eur J Cardiothorac Surg       Date:  2006-05-24       Impact factor: 4.191

2.  Patterns of surgical care of lung cancer patients.

Authors:  Alex G Little; Valerie W Rusch; James A Bonner; Laurie E Gaspar; Mark R Green; W Richard Webb; Andrew K Stewart
Journal:  Ann Thorac Surg       Date:  2005-12       Impact factor: 4.330

3.  European trends in preoperative and intraoperative nodal staging: ESTS guidelines.

Authors:  P De Leyn; D Lardinois; P Van Schil; R Rami-Porta; B Passlick; M Zielinski; D Waller; T Lerut; W Weder
Journal:  J Thorac Oncol       Date:  2007-04       Impact factor: 15.609

4.  Does the extent of lymph node dissection influence outcome in patients with stage I non-small-cell lung cancer?

Authors:  Christophe Doddoli; Adrian Aragon; Fabrice Barlesi; Bruno Chetaille; Stéphane Robitail; Roger Giudicelli; Pierre Fuentes; Pascal Thomas
Journal:  Eur J Cardiothorac Surg       Date:  2005-04       Impact factor: 4.191

5.  Postoperative survival and the number of lymph nodes sampled during resection of node-negative non-small cell lung cancer.

Authors:  Michelle S Ludwig; Michael Goodman; Daniel L Miller; Peter A S Johnstone
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

6.  A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer.

Authors:  Yi long Wu; Zhi-fan Huang; Si-yu Wang; Xue-ning Yang; Wei Ou
Journal:  Lung Cancer       Date:  2002-04       Impact factor: 5.705

7.  Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial.

Authors:  Mark S Allen; Gail E Darling; Taine T V Pechet; John D Mitchell; James E Herndon; Rodney J Landreneau; Richard I Inculet; David R Jones; Bryan F Meyers; David H Harpole; Joe B Putnam; Valerie W Rusch
Journal:  Ann Thorac Surg       Date:  2006-03       Impact factor: 4.330

8.  Impact of radical systematic mediastinal lymphadenectomy on tumor staging in lung cancer.

Authors:  J R Izbicki; B Passlick; O Karg; C Bloechle; K Pantel; W T Knoefel; O Thetter
Journal:  Ann Thorac Surg       Date:  1995-01       Impact factor: 4.330

9.  Incidence of local recurrence and second primary tumors in resected stage I lung cancer.

Authors:  N Martini; M S Bains; M E Burt; M F Zakowski; P McCormack; V W Rusch; R J Ginsberg
Journal:  J Thorac Cardiovasc Surg       Date:  1995-01       Impact factor: 5.209

10.  Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer.

Authors:  Ajeet Gajra; Nancy Newman; Gary P Gamble; Leslie J Kohman; Stephen L Graziano
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544

View more
  44 in total

1.  Comparative study of systematic thoracoscopic lymphadenectomy and conventional thoracotomy in resectable non-small cell lung cancer.

Authors:  Wei Wang; Weiqiang Yin; Wenlong Shao; Gening Jiang; Qun Wang; Lunxu Liu; Deruo Liu; Zheng Wang; Zhihua Zhu; Hanzhang Chen; Jianxing He
Journal:  J Thorac Dis       Date:  2014-01       Impact factor: 2.895

2.  Intrapulmonary lymph node retrieval: unclear benefit for aggressive pathologic dissection.

Authors:  Christina Brzezniak; Giuseppe Giaccone
Journal:  Transl Lung Cancer Res       Date:  2012-12

Review 3.  Towards optimal pathologic staging of resectable non-small cell lung cancer.

Authors:  Raymond U Osarogiagbon; Gail E Darling
Journal:  Transl Lung Cancer Res       Date:  2013-10

4.  Selective mediastinal lymphadenectomy without intraoperative frozen section examinations for clinical stage I non-small-cell lung cancer: retrospective study of 403 cases.

Authors:  Wei Jiang; Xiaoke Chen; Junjie Xi; Qun Wang
Journal:  World J Surg       Date:  2013-02       Impact factor: 3.352

5.  Predicting survival of patients with resectable non-small cell lung cancer: Beyond TNM.

Authors:  Raymond U Osarogiagbon
Journal:  J Thorac Dis       Date:  2012-04-01       Impact factor: 2.895

6.  Size and histologic characteristics of lymph node material retrieved from tissue discarded after routine pathologic examination of lung cancer resection specimens.

Authors:  Raymond U Osarogiagbon; Robert A Ramirez; Christopher G Wang; Laura E Miller; Laura McHugh; Courtney A Adair; Matthew P Smeltzer; Xinhua Yu; Allen Berry
Journal:  Ann Diagn Pathol       Date:  2014-02-10       Impact factor: 2.090

7.  Analysis of first recurrence and survival in patients with stage I non-small cell lung cancer treated with surgical resection or stereotactic radiation therapy.

Authors:  Traves D Crabtree; Varun Puri; Clifford Robinson; Jeffrey Bradley; Stephen Broderick; G Alexander Patterson; Jingxia Liu; Joanne F Musick; Jennifer M Bell; Michael Yang; Bryan F Meyers
Journal:  J Thorac Cardiovasc Surg       Date:  2014-01-02       Impact factor: 5.209

8.  Can lymph node evaluation be performed well by video-assisted thoracic surgery?

Authors:  Zhenrong Zhang; Hongxiang Feng; Xiaowei Wang; Chaoyang Liang; Deruo Liu
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-02       Impact factor: 4.553

Review 9.  Treatment of early stage non-small cell lung cancer: surgery or stereotactic ablative radiotherapy?

Authors:  Esengül Koçak Uzel; Ufuk Abacıoğlu
Journal:  Balkan Med J       Date:  2015-01-01       Impact factor: 2.021

10.  Socioeconomic risk factors for long-term mortality after pulmonary resection for lung cancer: an analysis of more than 90,000 patients from the National Cancer Data Base.

Authors:  Onkar V Khullar; Theresa Gillespie; Dana C Nickleach; Yuan Liu; Kristin Higgins; Suresh Ramalingam; Joseph Lipscomb; Felix G Fernandez
Journal:  J Am Coll Surg       Date:  2014-10-27       Impact factor: 6.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.